Boston, MA – Bacterial infections that don’t respond to antibiotics are of rising concern, as is sepsis — the immune system’s last-ditch, failed attack on infection that ends up being lethal itself. Reporting online in Nature on July 7, researchers at Boston Children’s Hospital describe new potential avenues for controlling both sepsis and the runaway bacterial infections that provoke it.
Sepsis kills a quarter million people each year in the U.S. and is the largest killer of newborns and children worldwide. Like antibiotic-resistant infections, it has no good treatment. Through meticulous experiments, scientists in Boston Children’s Program in Cellular and Molecular Medicine (PCMM) reveal the final cellular events necessary for both sepsis and stemming the bacterial attack.
Recent research has shown that at any sign of bacterial invasion, protein complexes called inflammasomes are activated. This activation triggers a process called pyroptosis — the infected cells explode open, releasing bacteria as well as chemical signals that sound an immune alarm. But there’s a balance: too strong an alarm can trigger sepsis, causing fatal blood-vessel and organ damage.
“The immune system is trying like hell to control the infection, but if the bacteria win out, the immune response can kill the patient,” explains Judy Lieberman, MD, PhD, senior investigator on the study together with Hao Wu, PhD, also in the PCMM. “Most attempts to quiet the immune response haven’t worked in treating sepsis in the clinic, because the parts that trigger it haven’t been well understood.”
Once activated, inflammasomes activate enzymes called caspases that cut a molecule called gasdermin D in two. This cleavage unleashes gasdermin D’s active fragment, known as gasdermin-D-NT. But how this causes pyroptosis hasn’t been known.
Lieberman, Wu and their colleagues now show that gasdermin-D-NT packs a one-two punch. On the one hand, it perforates the membranes of the bacteria that are infecting cells and kills them. It also punches holes in the membrane of the host cell, causing pyroptosis — killing the cell and releasing bacteria and immune alarm signals. Nearby uninfected cells are left unscathed, the team found.
Second, the team discovered that gasdermin-D-NT directly kills bacteria outside of cells, including E. coli, S. aureus and Listeria. In a dish, this happened quickly — within five minutes.
The results now need to be replicated in animal models of infection and sepsis, but Lieberman believes that understanding how gasdermin-D-NT works could be harnessed to help treat highly dangerous bacterial infections.
“Because of widespread antibiotic resistance, we have to think about other strategies,” Lieberman says. “Since the fragment kills bacteria but not uninfected host cells, one can imagine injecting the fragment directly, especially to treat a localized infection involving antibiotic-resistant bacteria.”
For sepsis, Lieberman speculates about ways of inhibiting or blocking gasdermin-D-NT, such as with antibodies or strategies targeting caspase enzymes.
Xing Liu, PhD, Zhibin Zhang, PhD and Jianbin Ruan, PhD are co-first authors on the paper. The study was funded by the National Institutes of Health (grant R01AI123265).
About Boston Children’s Hospital
Boston Children’s Hospital is home to the world’s largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including seven members of the National Academy of Sciences, 11 members of the Institute of Medicine and 10 members of the Howard Hughes Medical Institute comprise Boston Children’s research community. Founded as a 20-bed hospital for children, Boston Children’s today is a 404-bed comprehensive center for pediatric and adolescent health care. Boston Children’s is also the primary pediatric teaching affiliate of Harvard Medical School. For more, visit our Vector and Thriving blogs and follow us on our social media channels: @BostonChildrens, @BCH_Innovation, Facebook and YouTube.
- ### -
CONTACT: Keri Stedman
Boston Children’s Hospital
617-919-3110 | Keri.Stedman@childrens.harvard.edu